Tenpoint Therapeutics, Ltd.

This page is intended for US audiences only.

Tenpoint Therapeutics, Ltd. is a global commercial ophthalmic pharmaceutical company focused on the commercialization of YUVEZZI™ (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%, the first and only dual-agent eye drop for the treatment of presbyopia, a condition that affects nearly 128 million people in the U.S. and approximately 2 billion people globally.

By understanding real-world needs and partnering with eye care professionals, Tenpoint is working to bring innovation to the aging eye.

Tenpoint Therapeutics’ leadership team includes ophthalmic industry luminaries with track records of successful approval and commercialization of blockbuster treatments.